Drug · CHEMBL141
LAMIVUDINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LAMIVUDINE. Drugs and targets, record CHEMBL141. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL141
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Epivir, Epivir-hbv, Lamivudine component of /zidovudine teva, Lamivudine component of cimduo, Lamivudine component of combivir, Lamivudine component of delstrigo, Lamivudine component of dovato, Lamivudine component of dutrebis, Lamivudine component of epzicom, Lamivudine component of kivexa, Lamivudine component of symfi, Lamivudine component of temixys, Lamivudine component of triumeq, Lamivudine component of trizivir, Lamivudine teva, Lamivudine teva pharma b.v., Zeffix
- ChEMBL
- Other names
- 3TC, BCH 189, (-)-, GR 109714X, GR-109714X, GR109714X, Lamivudina, Lamivudine teva, Lamivudinum, NSC-760061, Virolam
- ChEMBL
- Open Targets' highest stage
- Approval, for 9 of its 35 diseases, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases35
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| HIV infectious disease | Approval | DailyMed, EMA Human Drugs, FDA, PMDA and TTD | 330 | 258 | https://conductscience.org/library/drugs?q=MONDO_0005109 |
| hepatitis B virus infection | Approval | DailyMed, EMA Human Drugs and PMDA | 48 | 36 | https://conductscience.org/library/drugs?q=MONDO_0005344 |
| chronic hepatitis B virus infection | Approval | DailyMed, EMA Human Drugs and PMDA | 30 | 17 | https://conductscience.org/library/drugs?q=MONDO_0005366 |
| HIV-1 infection | Approval | DailyMed and FDA | 21 | 11 | https://conductscience.org/library/drugs?q=EFO_0000180 |
| tuberculosis | Phase 3 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=MONDO_0018076 |
| AIDS | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0012268 |
| cirrhosis of liver | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0005155 |
| amyotrophic lateral sclerosis | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0004976 |
| Aicardi-Goutieres syndrome | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0018866 |
| Alzheimer disease | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0004975 |
1 to 10 of 35Source Open Targets
See all 35 diseasesTrials562
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00074581 | Preventing Sexual Transmission of HIV With Anti-HIV Drugs | Phase 3 | 3,526 | 2016-10-31 | lamivudine | Its name | ClinicalTrials.gov |
| NCT00118898 | Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults | Phase 3 | 1,864 | 2011-01-10 | lamivudine | Its name | ClinicalTrials.gov |
| NCT00342355 | Antiretroviral Therapy for Advanced HIV Disease in South Africa | Phase 4 | 1,771 | 2013-04-16 | lamivudine | Its name | ClinicalTrials.gov |
| NCT00099359 | Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission | Phase 3 | 1,735 | 2012-12-04 | lamivudine | Its name | ClinicalTrials.gov |
| NCT00084136 | Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings | Phase 4 | 1,571 | 2011-08-09 | lamivudine | Its name | ClinicalTrials.gov |
| NCT02028676 | Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa | Phase 4 | 1,206 | 2014-06-06 | lamivudine | Its name | ClinicalTrials.gov |
| NCT00098293 | Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine | Phase 3 | 916 | 2012-10-05 | lamivudine | Its name | ClinicalTrials.gov |
| NCT01263015 | A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial) | Phase 3 | 844 | 2014-07-02 | lamivudine | Its name | ClinicalTrials.gov |
| NCT00255840 | Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities | 812 | 2011-06-16 | lamivudine | Its name | ClinicalTrials.gov | |
| NCT02275780 | Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) | Phase 3 | 769 | 2018-10-23 | lamivudine | Its name | ClinicalTrials.gov |
1 to 10 of 562
See all 562 trialsComparisons in its trials149
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Early-ART vs Delayed-ART: serious adverse events | 526 of 886 | 522 of 877 | 1,763 | NCT00074581 | Trial comparisons |
| Clinically Driven Monitoring (CDM) vs Laboratory Plus Clinical Monitoring (LCM): LCM vs CDM: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV | 283 of 606 | 282 of 600 | 1,206 | NCT02028676 | Trial comparisons |
| Clinically Driven Monitoring (CDM) vs Laboratory Plus Clinical Monitoring (LCM): LCM vs CDM: Disease Progression to a New WHO Stage 4 Event or Death | 47 of 606 | 39 of 600 | 1,206 | NCT02028676 | Trial comparisons |
| Clinically Driven Monitoring (CDM) vs Laboratory Plus Clinical Monitoring (LCM): LCM vs CDM, Induction ART: Cessation of First-line Regimen for Clinical/Immunological Failure | 28 of 606 | 35 of 600 | 1,206 | NCT02028676 | Trial comparisons |
| DTG 50 mg Plus ABC/3TC 600/300 mg Once Daily vs EFV/TDF/FTC 600/200/300 mg Once Daily: serious adverse events | 65 of 414 | 60 of 419 | 833 | NCT01263015 | Trial comparisons |
| Antiretroviral Therapy Monitored by Medical Officer vs Antiretroviral Therapy Managed by Primary Health Care Nurse: serious adverse events | 126 of 408 | 153 of 404 | 812 | NCT00255840 | Trial comparisons |
| Doravirine 100 mg vs Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg: deaths from any cause | 3 of 385 | 3 of 384 | 769 | NCT02275780 | Trial comparisons |
| Doravirine 100 mg vs Daurunavir 800 mg + Ritonavir 100 mg → Doravirine 100 mg: serious adverse events | 45 of 383 | 49 of 383 | 766 | NCT02275780 | Trial comparisons |
| Continued Cotrimoxazole Prophylaxis vs Stopped Cotrimoxazole Prophylaxis: Cotrimoxazole: New WHO Stage 3 or 4 Event or Death | 8 of 376 | 19 of 382 | 758 | NCT02028676 | Trial comparisons |
| Continued Cotrimoxazole Prophylaxis vs Stopped Cotrimoxazole Prophylaxis: Cotrimoxazole: New WHO Stage 4 Event or Death | 4 of 376 | 7 of 382 | 758 | NCT02028676 | Trial comparisons |
1 to 10 of 149
See all 149 comparisons in its trialsPapers from its trials479
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials4
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Category Fluency | 1 | 0 | ConductCognition |
| Selective Reminding Task | 1 | 0 | ConductCognition |
| Short Story Recall | 1 | 0 | ConductCognition |
| Symbol Coding | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL141
GET https://conductscience.org/api/drugs/v1/CHEMBL141/diseases?page=2